Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 2010

View Archived Issues

HG-829 reverses resistance to antineoplastic agents in vitro and in vivo

ONO-013105 synergizes with rituximab in models of MCL and advances in phase I trial

New inhibitors claimed of PI3K-alpha and PI3K-gamma

Korean scientists divulge new amide compounds for treatment of bone disorders

Unigene and GSK amend licensing agreement and advance PTH program to phase II in osteoporosis

Phase I data support safety of BIIB-021 plus trastuzumab in HER2-positive breast cancer

MLN-0905 has antitumor effects in murine model of diffuse large B-cell lymphoma

Proton MRS can measure potential biomarkers for delirium in brain

MGN-1601 enters phase I/II study in advanced renal cancer

FDA grants Hemispherx an extension to modify its NDA for Ampligen

Rifadin capsules filed in Japan for nontuberculous mycobacterial disease

Orion identifies novel inhibitors of MT-SP1

GlaxoSmithKline claims new monoamine reuptake inhibitors

New modulators of metabotropic glutamate mGlu2 receptor discovered

Amarillo Biosciences completes enrollment in phase II trial of interferon alfa lozenges

Phase I safety data released on Immunovaccine's DPX-0907 cancer vaccine

Tesaro gains development rights to antiemetic rolapitant hydrochloride

Tolerx begins phase I TRX-518 trial for the treatment of cancer

FDA accepts for review sNDA for Definity in stress echocardiography

Phase IIa results reported for Creabilis' CT-327 in atopic dermatitis

Pharmasset begins exploratory trial of PSI-7977 in chronic hepatitis C

Vivus responds to FDA's complete response letter regarding Qnexa

Roflumilast approved in Canada for severe COPD in adults

Evolva begins multiple-ascending-dose phase I trial of EV-077

Kiacta enters phase III trial for prevention of renal decline in AA amyloidosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.